Ultrasound-Targeted Therapy for Acute Myocardial Infarction

描述（由申请人提供）：急性心肌梗死是发达国家的主要死亡原因之一，并且正在迅速成为发展中国家的主要死亡原因。如果一个病人有24小时的介入医生，那么在胸痛发作后90-120分钟内打开梗死相关动脉（IRA）的几率是85%。大多数患者，即使在美国，也没有这样的设施，如果他们到达地区医院，可能会接受溶栓治疗，打开梗死相关动脉的成功率为60%。如果其他一些非侵入性和易于应用的治疗方法可以提高单独溶栓的成功率，使其接近经皮冠状动脉介入治疗所能达到的85%，这可能会对公共卫生产生重大影响。本提案的总体目标是开发用于微泡超声介导治疗急性心肌梗死的新型超声设备技术。本提案的具体目标是开发一种集成的体内治疗成像系统，以：1。在狒狒体内使用血管分流模型确定导致成功溶栓的最佳超声参数。2. 开发能够向血栓输送适当超声能量的治疗探头，以溶解血栓，减少再灌注后的微血栓栓塞。3. 将治疗探头与4D超声成像系统集成，该系统可以对体内微泡进行成像，并设置超声脉冲自动溶解血栓。4. 探讨急性冠状动脉闭塞时心肌微循环的机制，超声治疗心肌预防再灌注后的微血栓栓塞。这项建议是建立一个生物医学研究伙伴关系，由该国在各自领域的领导人参与。Steve Hanson博士（OHSU）是一位血栓专家，他使用创新的狒狒模型来研究血栓溶解。Thomas Porter医学博士（内布拉斯加州大学）是使用微泡和超声进行动脉血栓溶解的先驱。Robert Siegel医学博士（Cedars-Sinai， UCLA）描述了急性冠状动脉闭塞期间超声直接心肌保护的新发现，该发现独立于其对血栓的影响。Sanjiv Kaul医学博士（OHSU）是MCE领域的先驱，他开发了复杂的技术来评估微循环，包括测量无回流、量化局部心肌灌注和分子成像。Pierre Khuri-Yakub（斯坦福大学）是换能器技术的领导者，GE是超声系统的世界领导者。宋旭波（OHSU）是确定性跟踪算法方面的权威，该算法可以帮助将超声波传递到跳动的心脏的正确目标。

DESCRIPTION (provided by applicant): Acute myocardial infarction is one of the leading causes of death in the developed world and is fast becoming a leading cause of death even in the developing world. If a patient has access to a hospital with interventionalists on 24 hr a day call, the chances of opening an infarct-related artery (IRA) within 90-120 minutes of the onset of chest pain is 85%. Most patients, even in the US, do not have access to such facilities and if they arrive at a regional hospital are likely to receive thrombolytic therapy that has a success rate of 60% in opening the infarct-related artery. If some other non-invasive and easily applied treatment could enhance the success of thrombolytics alone and bring it closer to the 85% that can be achieved with percutaneous coronary interventions, it could have a major public health impact. The overall aim of this proposal is to develop novel ultrasound device technologies for microbubble-ultrasound mediated treatment of acute myocardial infarction. The specific aims of this proposal are to develop an integrated in vivo therapy-imaging system to: 1. Determine the optimal ultrasound parameters that cause successful thrombolysis in vivo using a vascular shunt model in baboons. 2. Develop therapy probe(s) that can deliver appropriate ultrasound energy to the thrombus in order to dissolve it and reduce microthromboembolism after reperfusion. 3. Integrate the therapy probe(s) with a 4D ultrasound imaging system that can image microbubbles in vivo and gate ultrasound pulses to automatically dissolve the thrombus. 4. Determine the mechanisms of myocardial microcirculation during acute coronary occlusion and prevent microthromboembolism after reperfusion by treating the myocardium with ultrasound. This proposal is for a Biomedical Research Parternership that involves the leaders in the country in their specific fields. Steve Hanson, PhD (OHSU) is an expert on thrombosis and has used innovative baboon models to study thrombolysis. Thomas Porter, MD (University of Nebraska) is a pioneer in the use of microbubbles and ultrasound for arterial thrombus dissolution. Robert Siegel, MD (Cedars-Sinai, UCLA) has described the novel findings of direct myocardial protection by ultrasound during acute coronary occlusion that is independent of its effect on the thrombus. Sanjiv Kaul, MD, (OHSU) has pioneered the field of MCE and has developed sophisticated techniques to assess the microcirculation, including measurement of no reflow, quantifying regional myocardial perfusion, and molecular imaging. Pierre Khuri-Yakub (Stanford) is a leader in transducer technology, and GE is a world leader in ultrasound systems. Xubo Song (OHSU) is an authority on deterministic tracking algorithms that can assist in delivery of ultrasound to the correct target in a beating heart. PUBLIC HEALTH RELEVANCE: Acute myocardial infarction (heart attack) is one of the leading causes of death in the developed world and is fast becoming a leading cause of death even in the developing world. The aim of this proposal is to develop an ultrasound system that can non-invasively and easily dissolve the clots within a coronary artery responsible for an infarction and treat the tissue that is not receiving blood because of the clot. In this proposal we have brought together world experts in their respective fields to develop such a system.